For the quarter ending 2025-09-30, SRZNW had -$9,055K decrease in cash & cash equivalents over the period. -$9,064K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -71,643 | 12,776 |
| Depreciation and amortization | 61 | 431 |
| Stock-based compensation | 1,005 | 1,828 |
| Non-cash operating lease expense | 450 | 901 |
| Loss on amendment and cancellation of warrants | 0 | 2,073 |
| Loss on execution of the 2025 pipe | 0 | 71,084 |
| Transaction costs allocated to pre-funded warrants and warrants issued in connection with the 2025 pipe and 2024 pipe | 0 | 2,777 |
| Change in fair value of tranche liability | -40,748 | 47,860 |
| Change in fair value of warrant liabilities | 20,924 | -56,698 |
| Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 pipe | 0 | 0 |
| Gain on settlement of tranche liability | 0 | 1,117 |
| Non-cash consideration received in connection with research service revenue | 230 | 462 |
| Gain on foreign currency remeasurement | 0 | 278 |
| Accounts receivable | 250 | -250 |
| Accounts receivable -related party | -251 | - |
| Prepaid expenses and other current assets | 681 | -763 |
| Other assets | -18 | -36 |
| Accounts payable | 184 | 48 |
| Accrued and other liabilities | 555 | -989 |
| Operating lease liabilities | -432 | -955 |
| Net cash used in operating activities | -9,040 | -15,392 |
| Purchases of property and equipment | 24 | 45 |
| Net cash used in investing activities | -24 | -45 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants in the 2025 pipe and 2024 pipe, net of transaction costs | 0 | 71,201 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 61 |
| Proceeds from issuance of common stock upon exercise of options | 9 | - |
| Net cash provided by financing activities | 9 | 71,262 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -9,055 | 55,825 |
| Cash and cash equivalents at beginning of period | 35,253 | - |
| Cash and cash equivalents at end of period | 82,023 | - |
Surrozen, Inc. DE (SRZNW)
Surrozen, Inc. DE (SRZNW)